查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012774

抗菌藥物市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、分子類型、抗菌頻譜、作用機轉、劑型、適應症、銷售通路及通路區分類）

Antibacterial Drugs Market by Drug Class, Route Of Administration, Molecule Type, Spectrum Of Activity, Mechanism of Action, Formulation, Indication, Point of Sale, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗菌藥物市場價值將達到 540.5 億美元，到 2026 年將成長至 564.7 億美元，到 2032 年將達到 745.3 億美元，複合年成長率為 4.69%。

主要市場統計數據
基準年 2025 540.5億美元
預計年份：2026年 564.7億美元
預測年份 2032 745.3億美元
複合年成長率 (%) 4.69%

探索抗菌療法在應對現代感染疾病挑戰中的關鍵作用和演變動態。

感染疾病病原體的出現和快速演變使抗菌治療成為全球醫療保健的重中之重。過去十年，人們對抗生素抗藥性的日益關注推動了相關研究和監管，催生了一系列旨在克服多重抗藥性細菌抗藥性的創新療法。在此背景下，本報告深入探討了抗菌治療趨勢的多方面動態，檢驗了科學突破、政策轉變和以患者為中心的需求如何相互作用，從而決定了治療方法。

顛覆性的技術進步和監管模式轉移正在塑造抗菌藥物研發和應用的未來。

抗菌藥物領域正經歷一場根本性的變革，這得益於技術、監管和臨床實踐領域創新成果的整合。計算生物學和人工智慧的進步正在革新靶點識別方式，使研究人員能夠以前所未有的速度預測抗藥性機制並最佳化先導化合物。同時，監管機構也開始實施加速核准流程和新的獎勵機制，以因應抗菌藥物研發進程緩慢的傳統現狀。這種監管轉變不僅加快了關鍵治療方法的普及，也促進了公私部門之間的合作。

評估 2025 年美國關稅政策對全球供應鏈和抗菌藥物取得的廣泛影響。

美國2025年實施的新關稅措施正在對全球抗菌藥物供應鏈產生連鎖反應，改變成本結構並影響採購決策。關鍵中間體關稅的提高推高了原料成本，迫使製造商重新評估戰略夥伴關係並尋求替代採購地點。因此，以往作為成本效益型生產中心的地區如今正努力在價格競爭力和監管合規之間尋求微妙的平衡。

對抗菌藥物市場細分的治療領域、給藥途徑、分子類型和其他關鍵因素進行全面分析。

從多個觀點分析抗菌藥物市場細分，可以獲得細緻的見解。藥物類別包括Aminoglycosides、BETA-內醯胺類、大環內酯類、奎諾酮、磺胺類藥物及四環黴素。其中，在Aminoglycosides藥物中，Amikacin、慶大霉素、鏈黴素和妥布黴素特別值得關注；BETA-內醯胺類藥物則包括碳青黴烯類、頭孢菌素類、單環單環胺基類和青黴素類。依給藥途徑分類，可以反映口服、注射和外用製劑的多種應用，每種製劑都適用於不同的病患需求和醫療環境。

對美洲、歐洲、中東和非洲以及亞太市場的區域促進因素、挑戰和成長前景進行策略分析。

由於流行病學、法規結構和醫療基礎設施存在顯著的區域差異，地理差異在抗菌藥物市場結構的形成中發揮著至關重要的作用。儘管美洲地區持續的研發投入已建構起強大的新型化合物產品線，但抗菌藥物抗藥性的不斷上升和巨大的價格壓力，使得合理用藥成為必要。支付方模式強調基於價值的契約，鼓勵生產商證明其藥物的臨床療效和成本效益。

主要創新者和市場領導概況：主要抗菌藥物生產商的策略定位和競爭力

抗菌藥物市場的競爭格局呈現出多元化的特點，既有跨國製藥公司，也有專業生物技術公司和領先的非專利生產商。領先的創新公司持續利用龐大的研發基礎設施和高通量篩檢平台，推動First-in-Class分子進入後期研發階段。同時，靈活的生技公司則憑藉其在噬菌體和胜肽類治療方法等新興治療方法的專業知識，建構針對新出現的抗藥性機制的特色產品系列。

為行業相關人員提供策略挑戰和戰術性建議，以推動創新、市場滲透和改善患者療效。

為了在抗菌藥物研發領域保持領先地位，相關人員必須優先投資核心能力建設，並促進跨部門合作。首先，透過以診斷主導的綜合方案加強抗菌藥物使用項目，可以最佳化患者療效，並延長現有藥物的臨床效用。同時，擴大與學術機構和受託研究機構的研究合作，可以加速發現新的作用機制，並降低研發管線被淘汰的風險。

採用整合多種一手和二手資料來源的穩健調查方法，確保對抗菌藥物市場有全面可靠的洞察。

本報告採用嚴謹的調查方法，旨在確保研究結果的有效性和可靠性。首先，報告整合了廣泛的一手研究數據，包括對關鍵意見領袖（KOL）、臨床醫生和供應鏈高管的深入訪談。此外，報告還對二手資料進行了全面審查，包括同行評審期刊、監管出版刊物和專有專利資料庫，以補充這些定性研究結果。

整合關鍵見解與未來展望：聚焦抗菌治療領域不斷演變中的主要機會與挑戰

本報告的全面分析重點闡述了定義抗菌藥物創新下一階段的幾個總體主題。應對抗菌藥物抗藥性這項迫切挑戰，需要持續投資於新型治療方法和協作管理框架。同時，不斷變化的監管環境和貿易政策凸顯了供應鏈彈性和跨境夥伴關係的重要性。相關人員，將更有利於把握新的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 抗菌藥物市場：依藥物類別分類

  • Aminoglycosides
    • Amikacin
    • 慶大霉素
    • 鏈黴素
    • 妥布黴素
  • BETA-內醯胺
    • 碳青黴烯類
    • 頭孢菌素
    • 單環胺基類抗生素
    • 青黴素
  • 大環內酯類
  • 奎諾酮
  • 磺胺類藥物
  • 四環黴素

第9章：抗菌藥物市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第10章 抗菌藥物市場：依分子類型分類

  • 品牌商品
  • 非專利的

第11章 抗菌藥物市場：依抗菌頻譜

  • 頻譜
  • 窄頻譜

第12章 抗菌藥物市場：依作用機轉分類

  • 細胞壁抑制劑
  • DNA抑制劑
  • 蛋白質合成抑制劑

第13章 抗菌藥物市場：依劑型分類

  • 膠囊
  • 液體
  • 粉末
  • 藥片

第14章 抗菌藥物市場：依適應症分類

  • 呼吸道感染疾病
  • 性行為感染傳染病
  • 皮膚感染疾病
  • 尿道感染

第15章 抗菌藥物市場：依銷售管道分類

  • 非處方藥
  • 處方藥

第16章 抗菌藥物市場：依分銷管道分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第17章 抗菌藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章 抗菌藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章 抗菌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章：美國：抗菌藥物市場

第21章 中國：抗菌藥物市場

第22章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Allecra Therapeutics GmbH
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Century Pharmaceuticals Ltd.
  • Cipla Limited
  • Debiopharm Group
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Entasis Therapeutics by Innoviva, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Iterum Therapeutics PLC
  • Johnson & Johnson Services, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Saphnix Life Sciences
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8012

The Antibacterial Drugs Market was valued at USD 54.05 billion in 2025 and is projected to grow to USD 56.47 billion in 2026, with a CAGR of 4.69%, reaching USD 74.53 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 54.05 billion
Estimated Year [2026] USD 56.47 billion
Forecast Year [2032] USD 74.53 billion
CAGR (%) 4.69%

Exploring the Critical Role and Evolutionary Dynamics of Antibacterial Therapies in Confronting Modern Infectious Disease Challenges

The emergence and rapid evolution of infectious pathogens have positioned antibacterial therapies at the forefront of global healthcare priorities. Over the past decade, escalating concerns regarding antimicrobial resistance have galvanized research efforts and regulatory scrutiny, spurring a new wave of innovation aimed at overcoming the resilience of multidrug-resistant organisms. Against this backdrop, this report delves into the multifaceted dynamics of the antibacterial drugs landscape, examining how scientific breakthroughs, policy shifts, and patient-centric demands converge to dictate the trajectory of both established and emerging therapies.

Incorporating both historical context and contemporary developments, the analysis traces the shifting paradigm from broad-spectrum agents to precision-targeted molecules, underscoring the critical interplay between efficacy, safety, and stewardship. Moreover, the introduction of novel modalities-including bacteriophage therapies and antimicrobial peptides-signals a renaissance in drug discovery that is reshaping traditional R&D pathways. By articulating the strategic imperatives for manufacturers, payers, and healthcare providers alike, this section establishes the foundational themes that resonate throughout the ensuing report.

Disruptive Technological Advancements and Regulatory Paradigm Shifts Shaping the Future Landscape of Antibacterial Therapy Development and Deployment

The antibacterial drugs sector is undergoing a profound transformation driven by converging technological, regulatory, and clinical innovations. Advances in computational biology and artificial intelligence are revolutionizing target identification, enabling researchers to predict resistance mechanisms and optimize lead compounds with unprecedented speed. Concurrently, regulatory bodies have begun to adopt accelerated approval pathways and novel incentive frameworks to counteract the historically slow pace of antibacterial drug development. This regulatory shift not only expedites access to critical therapies but also encourages collaboration between public agencies and private enterprises.

Furthermore, the integration of real-world evidence and digital health tools is enhancing post-launch surveillance and patient adherence, thereby reinforcing antimicrobial stewardship while ensuring optimal therapeutic outcomes. These pioneering approaches, coupled with cross-sector alliances that span academia, biotech, and established pharmaceutical giants, are redefining the contours of market entry and competitive strategy. As a result, industry stakeholders must continuously adapt to these dynamic forces to capitalize on emerging opportunities and mitigate the persistent challenges posed by resistant pathogens.

Assessing the Far-Reaching Consequences of 2025 United States Tariff Policies on Global Supply Chains and Access to Antibacterial Medications

The introduction of new tariff measures by the United States in 2025 has generated ripple effects throughout the global antibacterial supply chain, altering cost structures and influencing sourcing decisions. Higher duties on key intermediates have augmented raw material expenses, compelling manufacturers to reassess strategic partnerships and explore alternative procurement hubs. Consequently, regions that previously served as cost-effective production centers are now navigating a delicate balance between price competitiveness and regulatory compliance.

Moreover, the tariff landscape has intensified the need for supply chain diversification, prompting stakeholders to establish secondary manufacturing facilities and leverage regional free trade agreements. This strategic realignment not only safeguards against geopolitical volatility but also preserves continuity of supply for critical therapies. Simultaneously, heightened import costs have exerted upward pressure on list prices, necessitating enhanced negotiations with payers and healthcare systems. Ultimately, understanding the cumulative impact of these policies is essential for developing robust mitigation strategies that ensure both affordability and accessibility of antibacterial treatments worldwide.

Comprehensive Analysis of Therapeutic Classes, Administration Routes, Molecule Types and Other Key Factors Driving Segmentation in Antibacterial Markets

Market segmentation within the antibacterial drugs domain reveals nuanced insights when examined through multiple lenses. The classification by drug class spans aminoglycosides, beta-lactams, macrolides, quinolones, sulfonamides, and tetracyclines; within aminoglycosides, agents such as amikacin, gentamicin, streptomycin, and tobramycin warrant particular attention, while beta-lactams encompass carbapenems, cephalosporins, monobactams, and penicillins. Parallel differentiation by route of administration captures the diverse applications of oral, parenteral, and topical formulations, each aligning to distinct patient needs and care settings.

When evaluating molecule type, the juxtaposition of branded versus generic options underscores the ongoing tension between innovation incentives and cost containment. In terms of spectrum of activity, the choice between broad spectrum and narrow spectrum compounds drives prescribing behaviors and stewardship priorities. Mechanism of action further stratifies the market into cell wall inhibitors, DNA inhibitors, and protein synthesis inhibitors, each governing distinct therapeutic niches. The formulation dimension-ranging from capsules to liquids, powders, and tablets-reflects considerations around patient compliance and dosage precision. Indication-based segmentation highlights the burden of respiratory, sexually transmitted, skin, and urinary tract infections, delineating where unmet needs persist. Finally, the point of sale distinction between over-the-counter and prescription models, alongside the distribution channel analysis of offline outlets such as hospital and retail pharmacies versus online platforms, illuminates the evolving pathways through which antibacterial agents reach end users.

Strategic Examination of Regional Drivers, Challenges, and Growth Prospects Across the Americas, Europe, Middle East & Africa, and Asia-Pacific Markets

Geographic variations play a pivotal role in shaping the antibacterial drugs landscape, as regional epidemiology, regulatory frameworks, and healthcare infrastructures diverge significantly. In the Americas, sustained investment in research and development has yielded a robust pipeline of novel compounds, yet rising antimicrobial resistance rates and stringent pricing pressures necessitate ongoing stewardship initiatives. Payer models emphasize value-based contracting, encouraging manufacturers to demonstrate both clinical efficacy and cost-effectiveness.

Shifting to the Europe, Middle East & Africa region, a mosaic of regulatory regimes and healthcare delivery systems presents both opportunities and challenges. Western European markets benefit from well-established reimbursement mechanisms and collaborative antimicrobial resistance surveillance programs, whereas emerging economies within Africa and the Middle East grapple with access constraints and infrastructural gaps. Nevertheless, increasing public-private partnerships are beginning to address diagnostic bottlenecks and distribution inefficiencies.

Meanwhile, the Asia-Pacific arena is characterized by rapid market expansion driven by growing patient populations, rising incomes, and enhanced local manufacturing capabilities. Policymakers across the region are implementing stringent controls on antibiotic usage, while regional biotech clusters are accelerating indigenous innovation. As a result, stakeholders must adopt region-specific strategies that reconcile local regulatory requirements with global development objectives.

Profiling Leading Innovators and Market Leaders: Strategic Positioning and Competitive Dynamics Among Top Antibacterial Drug Manufacturers

The competitive landscape of antibacterial therapeutics features a blend of multinational pharmaceutical corporations, specialized biotechnology firms, and prominent generic manufacturers. Leading innovators continue to leverage extensive R&D infrastructures and high-throughput screening platforms to advance first-in-class molecules through late-stage development. Concurrently, agile biotech enterprises harness niche expertise in emerging modalities, such as bacteriophage and peptide-based therapies, carving out specialized portfolios that address pressing resistance mechanisms.

Generic players, supported by streamlined manufacturing processes and established distribution channels, remain integral to maintaining affordability and accessibility. Their capacity to swiftly introduce cost-effective alternatives upon patent expiry exerts downward pressure on overall treatment costs, fostering broader adoption in price-sensitive markets. The interplay between these cohorts drives dynamic partnerships, licensing agreements, and merger-acquisition activities, shaping an ecosystem where strategic collaboration and competitive differentiation coexist. Both large and small organizations must therefore navigate a terrain defined by technological convergence, evolving regulatory incentives, and shifting payer expectations.

Strategic Imperatives and Tactical Recommendations for Industry Stakeholders to Enhance Innovation, Market Penetration, and Patient Outcomes

To remain at the vanguard of antibacterial drug development, industry stakeholders must prioritize targeted investments in core capabilities while fostering cross-sector collaboration. Firstly, strengthening antimicrobial stewardship programs through integrated diagnostic-driven protocols will optimize patient outcomes and prolong the clinical utility of existing agents. Simultaneously, expanding research partnerships with academic institutions and contract research organizations can accelerate the discovery of novel mechanisms of action, mitigating pipeline attrition risks.

Operationally, diversifying supply chain networks by establishing dual-sourcing strategies and regional manufacturing hubs can enhance resilience against geopolitical disruptions and tariff impositions. Embracing digital-enabled clinical trials and real-world evidence platforms will streamline development timelines and inform adaptive trial designs. Furthermore, proactive engagement with regulatory authorities to shape incentive frameworks and clarifying approval pathways will expedite market entry for breakthrough therapies. Finally, aligning commercial models to value-based contracting and patient support initiatives can reinforce market access, driving sustainable growth and improved public health outcomes.

Robust Research Methodology Integrating Diverse Primary and Secondary Data Sources Ensuring Comprehensive and Reliable Antibacterial Market Insights

This report employs a rigorous research methodology designed to ensure the validity and reliability of its findings. Initially, the analysis integrated extensive primary research, including in-depth interviews with key opinion leaders, clinical practitioners, and supply chain executives. These qualitative insights were complemented by a thorough review of secondary sources, encompassing peer-reviewed journals, regulatory agency publications, and proprietary patent databases.

Quantitative validation was achieved through cross-referencing multiple data repositories and triangulating supply chain metrics with prescription volume statistics. Throughout the process, proprietary analytical frameworks were applied to assess market drivers, technology adoption curves, and competitive positioning. Data integrity was maintained via iterative fact-checking and peer review by domain experts, ensuring that conclusions reflect the most current industry developments. This methodological approach underpins the strategic recommendations and reinforces the credibility of the market insights presented.

Synthesis of Critical Findings and Future Perspectives Highlighting Key Opportunities and Challenges in the Evolving Antibacterial Therapeutics Landscape

Drawing together the extensive analyses contained herein, several overarching themes emerge that will define the next phase of antibacterial drug innovation. The imperative to overcome antimicrobial resistance necessitates continued investment in novel modalities and collaborative stewardship frameworks. At the same time, evolving regulatory landscapes and trade policies underscore the importance of supply chain agility and cross-border partnerships. Stakeholders who adeptly align research endeavors, commercial strategies, and patient-centric models will be best positioned to capture emerging opportunities.

As the industry contends with the delicate balance between innovation incentives and affordability pressures, the ability to adapt to regional nuances will prove crucial. Future success will hinge on integrated approaches that harness technological breakthroughs, data-driven insights, and strategic alliances. Ultimately, the resilience of the antibacterial drugs market will depend on sustained commitment across public and private sectors to deliver effective, accessible therapies that address the global burden of infectious disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibacterial Drugs Market, by Drug Class

  • 8.1. Aminoglycosides
    • 8.1.1. Amikacin
    • 8.1.2. Gentamicin
    • 8.1.3. Streptomycin
    • 8.1.4. Tobramycin
  • 8.2. Beta-Lactams
    • 8.2.1. Carbapenems
    • 8.2.2. Cephalosporins
    • 8.2.3. Monobactams
    • 8.2.4. Penicillins
  • 8.3. Macrolides
  • 8.4. Quinolones
  • 8.5. Sulfonamides
  • 8.6. Tetracyclines

9. Antibacterial Drugs Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical

10. Antibacterial Drugs Market, by Molecule Type

  • 10.1. Branded
  • 10.2. Generic

11. Antibacterial Drugs Market, by Spectrum Of Activity

  • 11.1. Broad Spectrum
  • 11.2. Narrow Spectrum

12. Antibacterial Drugs Market, by Mechanism of Action

  • 12.1. Cell Wall Inhibitors
  • 12.2. DNA Inhibitors
  • 12.3. Protein Synthesis Inhibitors

13. Antibacterial Drugs Market, by Formulation

  • 13.1. Capsules
  • 13.2. Liquid
  • 13.3. Powder
  • 13.4. Tablets

14. Antibacterial Drugs Market, by Indication

  • 14.1. Respiratory Infections
  • 14.2. Sexually Transmitted Infections
  • 14.3. Skin Infections
  • 14.4. Urinary Tract Infections

15. Antibacterial Drugs Market, by Point of Sale

  • 15.1. Over-The-Counter Drugs
  • 15.2. Prescription Drugs

16. Antibacterial Drugs Market, by Distribution Channel

  • 16.1. Offline
    • 16.1.1. Hospital Pharmacy
    • 16.1.2. Retail Pharmacy
  • 16.2. Online

17. Antibacterial Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Antibacterial Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Antibacterial Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Antibacterial Drugs Market

21. China Antibacterial Drugs Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbott Laboratories
  • 22.6. AbbVie Inc.
  • 22.7. Allecra Therapeutics GmbH
  • 22.8. Astellas Pharma Inc.
  • 22.9. AstraZeneca PLC
  • 22.10. Bausch Health Companies Inc.
  • 22.11. Bayer AG
  • 22.12. Bristol-Myers Squibb Company
  • 22.13. Century Pharmaceuticals Ltd.
  • 22.14. Cipla Limited
  • 22.15. Debiopharm Group
  • 22.16. Dr. Reddy's Laboratories Ltd.
  • 22.17. Eli Lilly and Company
  • 22.18. Entasis Therapeutics by Innoviva, Inc.
  • 22.19. F. Hoffmann-La Roche AG
  • 22.20. GlaxoSmithKline PLC
  • 22.21. Glenmark Pharmaceuticals Limited
  • 22.22. Hikma Pharmaceuticals PLC
  • 22.23. Iterum Therapeutics PLC
  • 22.24. Johnson & Johnson Services, Inc.
  • 22.25. Kyorin Pharmaceutical Co., Ltd.
  • 22.26. Lupin Limited
  • 22.27. Melinta Therapeutics LLC
  • 22.28. Merck & Co., Inc.
  • 22.29. Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
  • 22.30. Novartis AG
  • 22.31. Pfizer Inc.
  • 22.32. Sanofi S.A.
  • 22.33. Saphnix Life Sciences
  • 22.34. Shionogi & Co., Ltd.
  • 22.35. Sun Pharmaceutical Industries Limited
  • 22.36. Taj Pharmaceuticals Limited
  • 22.37. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMIKACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMIKACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY STREPTOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY STREPTOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOBRAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOBRAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOBRAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MONOBACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MONOBACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MONOBACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BROAD SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BROAD SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BROAD SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NARROW SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NARROW SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NARROW SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CELL WALL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CELL WALL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CELL WALL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DNA INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DNA INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DNA INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 254. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 293. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 294. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 295. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 306. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 308. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 310. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA ANTIBACTERIAL DRUGS MARKET